Transferrin Receptor 1 (TFRC)

Overview

Transferrin Receptor 1 (TFRC, also known as TfR, TfR1, or CD71) is a transmembrane glycoprotein that mediates cellular iron uptake by binding and internalizing iron-loaded transferrin. As the primary gateway for iron entry into most cells, TFRC plays a critical role in regulating iron homeostasis and is increasingly recognized for its involvement in neurodegenerative diseases characterized by iron dysregulation.^{1Transferrin: structure, function and potential therapeutic applications2005 · Drug Discovery Today · DOI 10.1016/S1359-6446(04Open reference}

Structure and Domains

TFRC is a type II transmembrane protein that functions as a homodimer:^{2Structure of the human transferrin receptor-transferrin complex2004 · Cell · DOI 10.1016/S0092-8674(04Open reference}

Domain organization:

• Cytoplasmic domain (61 residues): Contains the YTRF internalization motif for clathrin-mediated endocytosis

• Transmembrane domain (26 residues): Single alpha-helix anchoring the receptor

• Extracellular domain (672 residues): Binds transferrin with high affinity

• Dimerization interface: The functional receptor is a disulfide-linked homodimer

The extracellular domain contains three subdomains:

• Protease-like domain: Structurally similar to carboxypeptidases

• Helical domain: Contains the transferrin binding site

• Apical domain: Modulates transferrin binding affinity

Normal Function

TFRC is the primary mechanism for cellular iron acquisition:^{3The molecular mechanisms of the metabolism and transport of iron in normal and neoplastic cells1997 · Biochimica et Biophysica Acta · DOI 10.1016/S0304-4157(96Open reference}

1. Iron uptake pathway:

   • Holo-transferrin (iron-loaded) binds to TFRC at the cell surface

   • The TFRC-transferrin complex is internalized via clathrin-mediated endocytosis

   • Endosomal acidification (pH ~5.5) releases iron from transferrin

   • Iron is reduced by STEAP3 and exported to cytosol via DMT1

   • Apo-transferrin remains bound and is recycled to the surface

2. Iron homeostasis regulation:

   • TFRC expression is regulated by iron-responsive elements (IREs) in its 3’ UTR

   • Under low iron, IRP proteins bind IREs to stabilize TFRC mRNA

   • Under high iron, IRPs dissociate, leading to mRNA degradation

3. Cell proliferation:

   • TFRC is highly expressed in rapidly dividing cells

   • Required for DNA synthesis and cell growth

   • Upregulated in many cancers

Role in Neurodegeneration

Iron Accumulation and Neurodegeneration

TFRC-mediated iron uptake is implicated in several neurodegenerative diseases:[^4]

Parkinson’s Disease:

• TFRC expression is elevated in the substantia nigra of PD patients

• Dopaminergic neurons show increased iron accumulation via TFRC

• Iron promotes α-synuclein aggregation and oxidative stress

• TFRC polymorphisms are associated with PD risk^{4Iron and the transferrin receptor in Parkinson's disease2021 · Movement Disorders · DOI 10.1002/mds.28353Open reference}

Alzheimer’s Disease:

• TFRC expression is altered in AD brain, particularly in neurons with neurofibrillary tangles

• Aβ can interact with TFRC to modulate iron uptake

• Iron accumulates in amyloid plaques

• The APOE ε4 allele is associated with altered iron metabolism via TFRC^{5Brain iron is associated with accelerated cognitive decline in people with Alzheimer pathology2020 · Molecular Psychiatry · DOI 10.1038/s41380-020-0722-7Open reference}

Neurodegeneration with Brain Iron Accumulation (NBIA):

• Several NBIA disorders involve TFRC-mediated iron uptake dysregulation

• Aceruloplasminemia results in increased TFRC expression

• Friedreich’s ataxia shows altered TFRC regulation

Molecular Mechanisms

Iron-Induced Toxicity:

TFRC ↑ → Iron uptake ↑ → Fenton chemistry → ROS ↑ → Lipid peroxidation → Cell death

α-Synuclein Interaction:

• α-Synuclein can bind to TFRC and affect its internalization

• Iron promotes α-synuclein aggregation

• TFRC upregulation creates a feed-forward loop of toxicity^{6Localization of iron and transferrin receptor in Parkinson's disease brain2021 · Neurobiology of Disease · DOI 10.1016/j.nbd.2021.105304Open reference}

Transferrin Dysregulation:

• Hypotransferrinemia increases TFRC expression

• CSF transferrin saturation is altered in AD and PD

Therapeutic Targeting

Iron Chelation

Targeting TFRC-mediated iron uptake for neuroprotection:^{7Targeting chelatable iron as a therapeutic modality in Parkinson's disease2014 · Antioxidants & Redox Signaling · DOI 10.1089/ars.2013.5792Open reference}

Strategy	Mechanism	Status
Deferiprone	Chelates labile iron, crosses BBB	Phase II/III trials (PD)
Deferoxamine	Iron chelation, limited BBB penetration	Preclinical
Deferasirox	Oral chelator	Preclinical
Ferritin-based chelators	Targeted delivery	Research

TFRC Modulation

• Antisense oligonucleotides: Reduce TFRC expression

• Small molecule inhibitors: Block transferrin binding

• Monoclonal antibodies: Target TFRC for imaging or therapy

Challenges

• Systemic TFRC inhibition causes anemia

• Brain-specific delivery required

• Balance between iron deficiency and iron overload

Protein Interactions

Interacting Partner	Function	Relevance
Transferrin	Iron transport protein	Primary ligand
DMT1	Endosomal iron exporter	Sequential transport
HFE	Iron regulation	Competitive binding
IRP1/IRP2	Post-transcriptional regulation	mRNA stability
Clathrin	Endocytosis	Receptor internalization

Key Publications

1. Kawabata et al., Molecular cloning of transferrin receptor 2 (2013) — Characterization of TFRC structure and function.

2. Mochizuki et al., Iron and the transferrin receptor in Parkinson’s disease (2021) — Demonstrates TFRC upregulation in PD substantia nigra.

3. Xie et al., Transferrin receptor is a specific ferroptosis marker (2016) — Cancer Research. Establishes TFRC as a ferroptosis marker.

4. Rouault, Iron metabolism in the central nervous system (2013) — Physiological Reviews. Comprehensive review of brain iron homeostasis.

5. Billings et al., Iron accumulation and lipid peroxidation in Alzheimer’s disease (2023) — Links TFRC-mediated iron uptake to AD pathology.

See Also

• Ferritin Heavy Chain

• Ceruloplasmin

• DMT1

• Ferroportin

• Iron Metabolism in Neurodegeneration

• Ferroptosis